Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2014, Article ID 638747, 13 pages
http://dx.doi.org/10.1155/2014/638747
Research Article

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

1Biomarkers and Personalized Medicine Core Function Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan
2Discovery Biology, Oncology Product Creation Unit, Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan
3Biomarkers and Personalized Medicine Core Function Unit, Eisai Inc., 4 Corporate Drive, Andover, MA 01810, USA

Received 12 June 2014; Accepted 26 August 2014; Published 10 September 2014

Academic Editor: Giovanni Tallini

Copyright © 2014 Osamu Tohyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

The Supplementary Material has contained additional 2 tables and 8 figures: Supplementary Table S1 Kinase inhibition profile of lenvatinib. Supplementary Table S2 Molecular Profile of human differentiated thyroid cancer cell lines. Supplementary Fig. S1 Tumor growth curves in human thyroid cancer xenograft models. Supplementary Fig. S2 Immunohistochemical analysis of tumor microvessels in human differentiated thyroid cancer xenograft models. Supplementary Fig. S3 Immunohistochemical analysis of pericyte coverage in human differentiated thyroid cancer xenograft models. Supplementary Fig. S4 Antiproliferative activity of lenvatinib against human thyroid cancer cells in vitro. Supplementary Fig. S5 Quantitative PCR analysis of receptor tyrosine kinase mRNA expression in human differentiated thyroid cancer cell lines. Supplementary Fig. S6 Effect of lenvatinib on the phosphorylation of FRS2 in human differentiated thyroid cancer RO82-W-1 xenografts. Supplementary Fig. S7 Comparison of antitumor activity with antiangiogenesis activity of lenvatinib and sorafenib in the human differentiated thyroid cancer RO82-W-1 xenograft model. Supplementary Fig. S8 Effect of lenvatinib on the phosphorylation of RET in human medullary thyroid cancer TT xenografts.

  1. Supplementary Materials